Ozempic increased by 3.5% to nearly $970 for a month’s supply, and Mounjaro grew 4.5% to nearly $1,070 a month, according to data from 46brooklyn Research. The research organization has also noted an odd trend in 2024: Drug price deductions are canceling out the increases.
Novo Nordisk, the maker of Ozempic, told the outlet that market conditions and inflation affect list prices, and Mounjaro-maker Eli Lilly said its medication prices are based on value, efficacy and safety.
Both medications are in a popular class of drugs called GLP-1s, or glucagon-like peptide-1 receptor agonists.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
